MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.
Ginkgo Bioworks, a US-based microbe engineering services spinout of Massachusetts Institute of Technology, agreed to a reverse merger with special purpose acquisition company Soaring Eagle Acquisition Corp today, according to a regulatory filing.
The deal values Ginkgo at $15bn and includes a $775m private investment in public equity (Pipe) co-led by Baillie Gifford, Putnam Investments and Morgan Stanley Investment Management’s Counterpoint Global.
The Pipe financing also includes Ark Investment Management, Bain Capital’s public equity arm, Cascade Investment,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
